<DOC>
	<DOCNO>NCT00791921</DOCNO>
	<brief_summary>The objective study verify superiority efficacy ( American College Rheumatology 20 % : ACR20 ) investigate pharmacokinetics safety CDP870 versus placebo without coadministration MTX active RA patient MTX administrate .</brief_summary>
	<brief_title>Efficacy Confirmation Trial CDP870 Without Coadministration Methotrexate ( MTX ) Japanese Rheumatoid Arthritis ( RA )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<criteria>Subjects must diagnosis adultonset RA least 6 month longer 15 year duration define 1987 American College Rheumatology classification criterion . Subjects must active RA disease define : At least 6 tender joint 6 swollen joint ESR 28 mm/hour CRP 2.0 mg/dL Subjects fail respond resistant least one DMARD ( include MTX ) Subjects MTX administer reason ( incomplete response/safety concern ) Patients diagnosis inflammatory arthritis Patients secondary , noninflammatory type arthritis ( eg , osteoarthritis , fibromyalgia ) Patients currently , history , demyelinate convulsive disease central nervous system ( eg , multiple sclerosis , epilepsy ) Patients NYHA ( New York Heart Association ) Class III IV congestive heart failure Patients currently , history , tuberculosis Patients high risk infection ( current infectious disease , chronic infectious disease , history serious infectious disease ) Patients currently , history , malignancy Female patient breastfeed pregnant , childbearing potential Patients previously receive treatment 2 antiTNFα drug previously fail respond treatment 1 aintTNFα drug .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>Certolizumab Pegol</keyword>
	<keyword>Cimzia</keyword>
</DOC>